Borner, M M (2006). [Molecular targets in colon cancer]. Therapeutische Umschau, 63(4), pp. 243-8. Bern: Huber 10.1024/0040-5930.63.4.243
Full text not available from this repository. (Request a copy)Colorectal cancer is the second leading cause of cancer death in Switzerland. The nihilism that dominated the treatment of these patients for decades has been replaced by a measure of enthusiasm, given recent therapeutic advances. New anticancer drugs such as irinotecan and oxaliplatin have changed the standard chemotherapy treatment of metastatic colorectal cancer. However, the real hype has come from molecular targeted therapy. Identification of cellular processes characteristic of colon cancer has permitted therapeutic targeting with favorable therapeutic index. Inhibition of the epidermal growth factor receptor in the clinic has provided proof of principle that interruption of signal transduction cascades in patients has therapeutic potential. Angiogenesis, especially the vascular endothelial growth factor pathway, has been proven to be another highly successful molecular target. In this article, we will review molecular targets, which are under active clinical investigation in colon cancer.
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Borner, Markus |
ISSN: |
0040-5930 |
ISBN: |
16689454 |
Publisher: |
Huber |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:46 |
Last Modified: |
05 Dec 2022 14:14 |
Publisher DOI: |
10.1024/0040-5930.63.4.243 |
PubMed ID: |
16689454 |
Web of Science ID: |
A1980JK90400008 |
URI: |
https://boris.unibe.ch/id/eprint/18986 (FactScience: 1269) |
Actions (login required)
 |
Edit item |